Research context
What has been studied.
No registered human trial was identified under this exact name in the current review. Published work may be preclinical or indexed under another name.
Search indexed research for this compound ↗SR9009 (Stenabolic) is a small-molecule research product rather than a peptide.
Also known as sr9009
Research shortlist · Sep 12, 2026
No exact product basis had a qualifying vendor in the Sep 12, 2026 research snapshot.
Vendor records are available below, but the Sep 12, 2026 research snapshot did not support a same-product shortlist.
What it is
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues. The listed molecular formula is C20H24ClN3O4S. PepGrades separately preserves the catalog category because a chemical identity record does not establish a use, outcome, or product quality.
This label describes the available research record, not whether the compound is safe or effective for an individual.
Research context
No registered human trial was identified under this exact name in the current review. Published work may be preclinical or indexed under another name.
Search indexed research for this compound ↗Market context
SR9009 (Stenabolic) is commonly sold or discussed for a range of compound-specific research goals. That describes market demand, not proof that the compound is safe or effective.
Market demand and online discussion do not establish product quality, safety, or effectiveness.Same format. Same amount.
0 of 0 formats had a qualifying research shortlist on Sep 12, 2026. Vendor counts below reflect the available price observations.
Vendor profiles and catalog information are still available below.
Vendor directory
Grades describe the vendor record overall. They are not a test result for every product.
| Vendor | Grade | Compared offers | In stock when checked | Lowest effective package | Profile |
|---|---|---|---|---|---|
| Next ChemsNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
Sources and review
Last editorial review: Aug 30, 2026. Sources support the compound guide only and do not affect vendor grades.